Critical aspects of the Bayesian approach to phase I cancer trials

Statistics in Medicine

Volumn 27, Issue 13, 2008, Pages 2420-2439

  Neuenschwander, Beat ^a   Branson, Michael ^a   GsPoner, Thomas ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Continual reassessment method; Logistic model; Maximum tolerated dose

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; BAYES THEOREM; CLINICAL DECISION MAKING; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INTERMETHOD COMPARISON; LOGISTIC REGRESSION ANALYSIS; MATHEMATICAL MODEL; MAXIMUM TOLERATED DOSE; MONTE CARLO METHOD; MULTICENTER STUDY; NEOPLASM; PHASE 1 CLINICAL TRIAL; PROBABILITY; STATISTICAL ANALYSIS; TOXICITY TESTING;

ANTINEOPLASTIC AGENTS; BAYES THEOREM; CLINICAL TRIALS, PHASE I AS TOPIC; COMPUTER SIMULATION; HUMANS; MODELS, STATISTICAL; NEOPLASMS;

EID: 44949143122     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.3230     Document Type: Article

References (44)

1. Storer B. Design and analysis of phase I clinical trials. Biometrics 1989; 45:925-937.
2. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 1990; 46:33-48.
3. Dixon W, Mood A. A method for obtaining and analyzing sensitivity data. Journal of the American Statistical Association 1948; 43:109-126.
4. Rosenberger WF, Haines LM. Competing designs for phase I clinical trials: a review. Statistics in Medicine 2002; 21:2757-2770.
5. Ivanova A, Montazer-Haghighi A, Mohanty SG, Durham SD. Improved up-and-down designs for phase I trials. Statistics in Medicine 2003; 22:69-82.
6. Gasparini M, Eisele J. A curve-free method for phase I clinical trials. Biometrics 2000; 57:609-615.
7. O'Quigley J. Curve-free model-based continual reassessment method designs. Biometrics 2002; 58:245-249.
8. Leung DH, Wang YG. Isotonic designs for phase I trials. Controlled Clinical Trials 2001; 22:126-138.
9. Faries D. The continual reassessment method in cancer phase I clinical trials: a simulation study. Journal of Biopharmaceutical Statistics 1994; 4(2):147-164.
10. O'Quigley J, Shen L. Continual reassessment method: a likelihood approach. Biometrics 1996; 52:673-684.
11. Babb JS, Rogatko A, Zacks S. Cancer phase I clinical trials: efficient dose escalation with overdose control. Statistics in Medicine 1998; 17:1103-1120.
12. Zhou Y, Whitehead J. Practical implementation of Bayesian dose-escalation procedures. Drug Information Journal 2003; 37:45-59.
13. Zhou Y, Lucini M. Gaining acceptability for the Bayesian decision-theoretic approach in dose-escalation studies. Pharmaceutical Statistics 2005; 4:161-171.
14. Babb JS, Rogatko A. Patient specific dosing in a cancer phase I clinical trial. Statistics in Medicine 2001; 20:2079-2090.
15. Rogatko A, Babb JS, Tighiouart M, Khuri FR, Hudes G. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I. Clinical Cancer Research 2005; 11:15.
16. Loke Y-C, Tan S-B, Cai Y, Machin D. A Bayesian dose finding design for dual endpoint phase I trials. Statistics in Medicine 2006; 25:3-22.
17. Cheung YK, Chappell R. Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics 2000; 56:1177-1182.
18. Braun TM, Zheng Y, Thall PF. Determining a maximum-tolerated schedule of a cytotoxic agent. Biometrics 2005; 61:335-343.
19. Braun TM. Generalizing the TITE-CRM to adapt for early- and late-onset toxicities. Statistics in Medicine 2006; 25(12):2071-2083.
20. Legedza ATR, Ibrahim JG. Longitudinal design for phase I clinical trials using the continual reassessment method. Controlled Clinical Trials 2000; 21:574-588.
21. Piantadosi S, Liu G. Improved designs for dose escalation studies using pharmacokinetic measurements. Statistics in Medicine 1996; 15:1605-1618.
22. Legedza ATR, Ibrahim JG. Heterogeneity in phase I clinical trials: prior elicitation and computation using the continual reassessment method. Statistics in Medicine 2001; 20:867-882.
23. Whitehead J. Heterogeneity in phase I clinical trials: prior elicitation and computation using the continual reassessment method (letter to the editor). Statistics in Medicine 2002; 21:1172.
24. Kramar A, Lebecq A, Candalh E. Continual reassessment methods in phase I trials of the combination of two drugs in oncology. Statistics in Medicine 1999; 18:1849-1864.
25. Thall P, Millikan R, Mueller P, Lee S-J. Dose-finding with two agents in phase I oncology trials. Biometrics 2003; 59:487-496.
26. Whitehead J, Zhou Y, Mander A, Ritchie S, Sabin A, Wright A. An evaluation of Bayesian designs for dose-escalation studies in healthy volunteers. Statistics in Medicine 2006; 25(3):433-445.
27. Thall PF, Lee JJ, Tseng C-H, Estey EH. Accrual strategies for phase I trials with delayed patient outcome. Statistics in Medicine 1999; 18:1155-1169.
28. Chevret S. The continual reassessment method in cancer phase I clinical trials: a simulation study. Statistics in Medicine 1993; 12:1093-1108.
29. Zohar S, Chevret S. The continual reassessment method: comparison of Bayesian stopping rules for dose ranging studies. Statistics in Medicine 2001; 20:2827-2843.
30. Ishizuka N, Ohashi Y. The continual reassessment method and its applications: a Bayesian methodology for phase I cancer clinical trials. Statistics in Medicine 2001; 20:2661-2681.
31. Whitehead J, Brunier H. Bayesian decision procedures for dose determining experiments. Statistics in Medicine 1995; 14:885-893.
32. Patterson S, Francis S, Ireson M, Webber D, Whitehead J. A novel Bayesian decision procedure for early-phase dose-finding studies. Journal of Biopharmaceutical Statistics 1999; 9(4):583-597.
33. Leung DH, Wang YG. An extension of the continual reassessment method using decision theory. Statistics in Medicine 2002; 21:51-63.
34. Haines LM, Perevozskaya I, Rosenberger WF. Bayesian optimal designs for phase I clinical trials. Biometrics 2003; 59:591-600.
35. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health-care Evaluation. Wiley: U.K., 2004.
36. O'Quigley J. Retrospective analysis of sequential dose-finding designs. Biometrics 2005; 61:749-756.
37. Robert CP, Casella G. Monte Carlo Statistical Methods. Springer: New York, 2004.
38. Neuenschwander B, Gsponer T, Branson M. A Bayesian approach to phase I cancer trials. Technical Report 2006-05-11, Novartis Pharma AG, Basel, Switzerland, 2006.
39. Neuenschwander B, Capkun-Niggli G, Branson M, Spiegelhalter D. Using Historical Controls in Clinical Trials, in preparation.
40. Heyd JM, Carlin BP. Adaptive design improvements in the continual reassessment method for phase I studies. Statistics in Medicine 1999; 18:1307-1321.
41. Spiegelhalter D, Thomas A, Best N. WinBUGS 1.4.1. MRC Biostatistics Unit: Cambridge, U.K., 2005.
42. R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria, 2004. ISBN 3-900051-07-0.
43. Martin AD, Quinn KM. MCMCpack: Markov Chain Monte Carlo (MCMC) Package. R Package Version 0.6-4, 2005.
44. Smith AFM, Gelfand AE. Bayesian statistics without tears: a sampling-resampling perspective. The American Statistician 1992; 46(2):44-88.